Article Images (0)
×![]()
featured_play_listSave article to folder
X
Create new folder
Full Text
PDF
Table of Contents
Abstract
Abstract
Recurrent Clostridioides (Clostridium) difficile infections appear to be common and costly in France, according to findings of a Merck Sharp & Dohmefunded study published in the European Journal of Clinical Microbiology and Infectious Diseases. This nationwide cohort study used 2015 data from the French Health Insurance database to evaluate the predictors and cost burden of hospital readmission with recurrent C. difficile infection (rCDI) in France within 12 weeks after the index hospitalisation. Multivariate logistic regression analysis was used to investigate the risk factors for rCDI. Overall, 14.5% of the 14 739 patients who survived the index hospitalisation with CDI were readmitted with rCDI. Significant risk factors for readmission included previous history of CDI (adjusted odds ratio [aOR] 2.05; 95% CI 1.55, 2.71), age 65 years or over (aOR 1.34, 95% CI 1.21, 1.49), chronic renal failure (aOR 1.29; 95% CI 1.14, 1.46), and immunosuppression (aOR, 1.27; 95% CI 1.15, 1.41); all p<0.0001). The cumulative number of risk factors was also independently associated with the risk of readmission. Acute care costs in patients with rCDI were €5619* for readmissions with a primary diagnosis of rCDI and €4851 for readmissions with a secondary diagnosis of rCDI. The mean length of hospital stay was 11.3 and 16.8 days, respectively. The estimated nationwide cost of rCDI in 2015 was €14 946 632. "Readmissions with rCDI are commonly required in French patients discharged after an index episode and are responsible for a significant part of the global burden of CDI. Secondary prevention strategies—along with the use of vancomycin or fidaxomicin—should be discussed upon the index episode in patients cumulating two or more risk factors for readmission," concluded the authors.
PharmacoEconomics & Outcomes News 826, p26 - 20 Apr 2019 Recurrent C. difficile infections costly in France Recurrent Clostridioides (Clostridium) difficile infections appear to be common and costly in France, according to findings of a Merck Sharp & Dohmefunded study published in the European Journal of Clinical Microbiology and Infectious Diseases. This nationwide cohort study used 2015 data from the French Health Insurance database to evaluate the predictors and cost burden of hospital readmission with recurrent C. difficile infection (rCDI) in France within 12 weeks after the index hospitalisation. Multivariate logistic regression analysis was used to investigate the risk factors for rCDI. Overall, 14.5% of the 14 739 patients who survived the index hospitalisation with CDI were readmitted with rCDI. Significant risk factors for readmission included previous history of CDI (adjusted odds ratio [aOR] 2.05; 95% CI 1.55, 2.71), age 65 years or over (aOR 1.34, 95% CI 1.21, 1.49), chronic renal failure (aOR 1.29; 95% CI 1.14, 1.46), and immunosuppression (aOR, 1.27; 95% CI 1.15, 1.41); all p<0.0001). The cumulative number of risk factors was also independently associated with the risk of readmission. Acute care costs in patients with rCDI were €5619* for readmissions with a primary diagnosis of rCDI and €4851 for readmissions with a secondary diagnosis of rCDI. The mean length of hospital stay was 11.3 and 16.8 days, respectively. The estimated nationwide cost of rCDI in 2015 was €14 946 632. "Readmissions with rCDI are commonly required in French patients discharged after an index episode and are responsible for a significant part of the global burden of CDI. Secondary prevention strategies—along with the use of vancomycin or fidaxomicin—should be discussed upon the index episode in patients cumulating two or more risk factors for readmission," concluded the authors. * 2015 euros Dinh A, et al. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. European Journal of Clinical Microbiology and Infectious Diseases : 2 Apr 2019. Available from: URL: http://doi.org/10.1007/s10096-019-03552-9 803385886 1 PharmacoEconomics & Outcomes News 20 Apr 2019 No. 8261173-5503/19/0826-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Article Images (0)
×![]()
Bioz is the world’s most comprehensive AI search engine for scientific experimentation. The Bioz search engine offers researchers billions of data-driven product, technique, and protocol recommendations. Bioz taps into the latest advances in Artificial Intelligence (AI) – including Natural Language Processing (NLP), Machine Learning (ML) and Generative AI to mine and structure hundreds of millions of pages of complex and unstructured scientific papers. By harnessing the power of AI, Bioz provides researchers with an unprecedented amount of summarized scientific experimentation knowledge right at their fingertips, ultimately helping to speed up drug discovery and the rate of success in finding cures for diseases. Bioz is used by over 15 Million researchers from over 17,000 different universities and companies in 196 countries.
